134 related articles for article (PubMed ID: 15724801)
21. Efficacy of a new oral contraceptive containing drospirenone and ethinyl estradiol in the long-term treatment of hirsutism.
Batukan C; Muderris II
Fertil Steril; 2006 Feb; 85(2):436-40. PubMed ID: 16595223
[TBL] [Abstract][Full Text] [Related]
22. Treatment of hirsutism with ethinyl estradiol-desogestrel contraceptive pills has beneficial effects on the lipid profile and improves insulin sensitivity.
Escobar-Morreale HF; Lasunción MA; Sancho J
Fertil Steril; 2000 Oct; 74(4):816-9. PubMed ID: 11020530
[TBL] [Abstract][Full Text] [Related]
23. Evidence that treatment with monophasic oral contraceptive formulations containing ethinylestradiol plus gestodene reduces bone resorption in young women.
Paoletti AM; Orrù M; Floris S; Mannias M; Vacca AM; Ajossa S; Guerriero S; Melis GB
Contraception; 2000 Apr; 61(4):259-63. PubMed ID: 10899481
[TBL] [Abstract][Full Text] [Related]
24. Short-term treatment of hirsutism related to micropolycystic ovary syndrome with a combination type oral contraceptive containing desogestrel.
Sobbrio GA; Granata A; D'Arrigo F; Arena D; Trimarchi F; Granese D; Pullè C
Acta Eur Fertil; 1989; 20(1):35-7. PubMed ID: 2528880
[TBL] [Abstract][Full Text] [Related]
25. Comparison of spironolactone-oral contraceptive versus cyproterone acetate-estrogen regimens in the treatment of hirsutism.
Erenus M; Yücelten D; Gürbüz O; Durmuşoğlu F; Pekin S
Fertil Steril; 1996 Aug; 66(2):216-9. PubMed ID: 8690104
[TBL] [Abstract][Full Text] [Related]
26. Spironolactone and estrogen-progestin therapy for hirsutism.
Board JA; Rosenberg SM; Smeltzer JS
South Med J; 1987 Apr; 80(4):483-6. PubMed ID: 3563583
[TBL] [Abstract][Full Text] [Related]
27. Prostate-specific antigen in female serum, a potential new marker of androgen excess.
Melegos DN; Yu H; Ashok M; Wang C; Stanczyk F; Diamandis EP
J Clin Endocrinol Metab; 1997 Mar; 82(3):777-80. PubMed ID: 9062481
[TBL] [Abstract][Full Text] [Related]
28. The increased circulating prostate-specific antigen concentrations in women with hirsutism do not respond to acute changes in adrenal or ovarian function.
Escobar-Morreale HF; Serrano-Gotarredona J; Avila S; Villar-Palasí J; Varela C; Sancho J
J Clin Endocrinol Metab; 1998 Jul; 83(7):2580-4. PubMed ID: 9661648
[TBL] [Abstract][Full Text] [Related]
29. Comparison of the clinical efficacy and safety of flutamide versus flutamide plus an oral contraceptive in the treatment of hirsutism.
Taner C; Inal M; Başogul O; Onoglu A; Karanfil C; Tinar S; Ispahi C
Gynecol Obstet Invest; 2002; 54(2):105-8. PubMed ID: 12566753
[TBL] [Abstract][Full Text] [Related]
30. A comparison between spironolactone and spironolactone plus finasteride in the treatment of hirsutism.
Keleştimur F; Everest H; Unlühizarci K; Bayram F; Sahin Y
Eur J Endocrinol; 2004 Mar; 150(3):351-4. PubMed ID: 15012621
[TBL] [Abstract][Full Text] [Related]
31. The effects of spironolactone on adrenal steroidogenesis in hirsute women.
Serafini P; Lobo RA
Fertil Steril; 1985 Nov; 44(5):595-9. PubMed ID: 2996951
[TBL] [Abstract][Full Text] [Related]
32. Comparison of the efficiency of anti-androgenic regimens consisting of spironolactone, Diane 35, and cyproterone acetate in hirsutism.
Sert M; Tetiker T; Kirim S
Acta Med Okayama; 2003 Apr; 57(2):73-6. PubMed ID: 12866746
[TBL] [Abstract][Full Text] [Related]
33. Long-term treatment of hirsutism: desogestrel compared with cyproterone acetate in oral contraceptives.
Porcile A; Gallardo E
Fertil Steril; 1991 May; 55(5):877-81. PubMed ID: 1827074
[TBL] [Abstract][Full Text] [Related]
34. Mild adrenal and ovarian steroidogenic abnormalities in hirsute women without hyperandrogenemia: does idiopathic hirsutism exist?
Escobar-Morreale HF; Serrano-Gotarredona J; García-Robles R; Sancho J; Varela C
Metabolism; 1997 Aug; 46(8):902-7. PubMed ID: 9258272
[TBL] [Abstract][Full Text] [Related]
35. A comparative metabolic study of two low-estrogen-dose oral contraceptives containing desogestrel or gestodene progestins.
Crook D; Godsland IF; Worthington M; Felton CV; Proudler AJ; Stevenson JC
Am J Obstet Gynecol; 1993 Nov; 169(5):1183-9. PubMed ID: 8238183
[TBL] [Abstract][Full Text] [Related]
36. Spironolactone in combination drug therapy for unresponsive hirsutism.
Pittaway DE; Maxson WS; Wentz AC
Fertil Steril; 1985 Jun; 43(6):878-82. PubMed ID: 3158552
[TBL] [Abstract][Full Text] [Related]
37. Serum levels of androstanediol glucuronide, total testosterone, and free testosterone in hirsute women.
Khoury MY; Baracat EC; Pardini DP; Vieira JG; de Lima GR
Fertil Steril; 1994 Jul; 62(1):76-80. PubMed ID: 8005308
[TBL] [Abstract][Full Text] [Related]
38. Combination gonadotropin-releasing hormone agonist and oral contraceptive therapy improves treatment of hirsute women with ovarian hyperandrogenism.
Elkind-Hirsch KE; Anania C; Mack M; Malinak R
Fertil Steril; 1995 May; 63(5):970-8. PubMed ID: 7720941
[TBL] [Abstract][Full Text] [Related]
39. Single and multiple administration of a new triphasic oral contraceptive to women: pharmacokinetics of ethinyl estradiol and free and total testosterone levels in serum.
Kuhnz W; Sostarek D; Gansau C; Louton T; Mahler M
Am J Obstet Gynecol; 1991 Sep; 165(3):596-602. PubMed ID: 1892184
[TBL] [Abstract][Full Text] [Related]
40. Hirsutism--a low dose spironolactone therapy.
Vĕtr M
Acta Univ Palacki Olomuc Fac Med; 1989; 122():239-45. PubMed ID: 2530821
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
